Dr. Agarwal's Health Care has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The healthcare provider held an analyst and earnings conference call on August 4, 2026, to discuss the operational and financial performance for the period. This disclosure ensures transparency for investors regarding the company’s latest quarterly standing in the eye care sector.

The filing was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dr. Agarwal's Health Care Limited submitted the notice to both BSE Limited and National Stock Exchange of India Limited. The audio recording of the conference call is available on the company’s official website for investor access.

Key Disclosures

The primary focus of the communication was the availability of the earnings call recording detailing the Q4FY26 results. Below are the specific details provided in the regulatory filing:

Thanikainathan Arumugam, Company Secretary and Compliance Officer, signed the disclosure. The document confirms that the audio recording can be accessed via the designated link on the corporate website, ensuring compliance with listing obligations.

Dr. Agarwal's Health Care Limited will host an earnings and analyst conference call on August 04, 2026, at 05:30 PM IST to discuss its financial performance for the quarter ended June 30, 2026. The company's Board of Directors is scheduled to meet on the same day to consider and approve the unaudited standalone and consolidated financial results for the period. Investors seeking insights into the company's latest operational and financial metrics should note that the trading window remains closed until 48 hours after the announcement of these results, as per the company's Code of Conduct for Prevention of Insider Trading.

The conference call is scheduled from 05:30 PM to 06:30 PM IST. Dr. Adil Agarwal, Whole-time Director and Chief Executive Officer, Mr. Yashwanth Venkat, Chief Financial Officer, and Ms. Aashna Dharia, Head of Investor Relations, will represent the company during the discussion. The event aims to provide clarity on the financial outcomes for the first quarter of FY27.

Conference Call Details

Participants can join the call via dial-in numbers provided for domestic and international attendees. The company has issued reference AHCL/2026-27/C030 in compliance with Regulation 29 and 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dial-in Information

An express join link via Diamond Pass is also available for registered participants. Attendees are requested to dial in ten minutes before the scheduled start time.

Regulatory Compliance

The intimation was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, on July 28, 2026. The information has been published on the company's website and submitted to both BSE Limited and National Stock Exchange of India Limited. The trading window closure ensures equitable information distribution among shareholders ahead of the public disclosure of the quarterly results.